Ventyx Biosciences, Inc.

NASDAQ:VTYX

2.2 (USD) • At close November 8, 2024
Bedrijfsnaam Ventyx Biosciences, Inc.
Symbool VTYX
Munteenheid USD
Prijs 2.2
Beurswaarde 155,472,086
Dividendpercentage 0%
52-weken bereik 1.79 - 11.48
Industrie Biotechnology
Sector Healthcare
CEO Dr. Raju S. Mohan Ph.D.
Website https://www.ventyxbio.com

An error occurred while fetching data.

Over Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease,

Vergelijkbare Aandelen

SNDL Inc. logo

SNDL Inc.

SNDL

1.98 USD

Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc.

RXRX

7.1 USD

Simulations Plus, Inc. logo

Simulations Plus, Inc.

SLP

30.59 USD

Varex Imaging Corporation logo

Varex Imaging Corporation

VREX

14.22 USD

Revance Therapeutics, Inc. logo

Revance Therapeutics, Inc.

RVNC

3.7 USD

BridgeBio Pharma, Inc. logo

BridgeBio Pharma, Inc.

BBIO

27.09 USD

Sharecare, Inc. logo

Sharecare, Inc.

SHCR

1.43 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)